Drug Profile
Brolucizumab - Novartis
Alternative Names: Beobyu; BEOVU; Beovu; Brolucizumab-dbll; ESBA-1008; RTH-258Latest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator ESBATech
- Developer Novartis
- Class Antibodies; Eye disorder therapies; Immunoglobulin Fv fragments; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Wet age-related macular degeneration
- Registered Diabetic macular oedema
- Phase III Diabetic retinopathy; Polypoidal choroidal vasculopathy; Retinal vein occlusion
Most Recent Events
- 27 Mar 2024 Pyxis Oncology sells the rights to royalties from the commercialization of brolucizumab to Novartis
- 28 Feb 2024 Novartis completes the phase III trial in Wet age-related macular degeneration (Treatment-naive) in China (Intravitreous) (NCT04047472)
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology